dcsimg Aranesp® (darbepoetin alfa) – Hemoglobin (Hb) Trends

› Email this page

The nephrology landscape continues to evolve
Mean quarterly Hb levels in 2011 and 20131

Mean quarterly Hb levels in 2011 and 2013

For patients with CKD on dialysis

  • Initiate Aranesp® treatment when the Hb level is < 10 g/dL.
  • Individualize dosing and use the lowest dose of Aranesp® sufficient to reduce the need for RBC transfusions.

Important Safety Information

WARNING - Chronic Kidney Disease:

  • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL
  • No trial has identified a hemoglobin target level, Aranesp® dose, or dosing strategy that does not increase these risks.
  • Use the lowest Aranesp® dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; RBC = red blood cell; Hb = hemoglobin.
Reference: 1. Data on file, Amgen; [OutcomesPlus database; July 2013].